SG301 + pomalidomide + dexamethasone

SG301 + pomalidomide + dexamethasone is an investigational triple-drug combination being evaluated as a therapy for relapsed or refractory multiple myeloma. SG301 is an experimental agent administered as an injection; while its specific molecular identity and mechanism are not fully disclosed in public sources, it is being studied in combination with pomalidomide (an immunomodulatory agent that inhibits tumor cell proliferation and enhances immune response) and dexamethasone (a corticosteroid with anti-inflammatory and cytotoxic effects). The combination is currently in phase III clinical trials in patients who have received at least one prior regimen including both lenalidomide and a proteasome inhibitor, reflecting efforts to improve outcomes in refractory myeloma[5][7][9][10].